Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens

WDAY

Chico's FAS Inc. (NYSE: CHS) – For an in-depth report on Chico's FAS Inc. follow: www.BullTrends.com/stockquote/CHS

Chico’s FAS Inc. closed down 8.50% on Thursday with about 15.1 million shares traded. The stock was one of the biggest decliners on the NYSE. Fourth quarter sales and earnings came in below expectations. The company reported a net income of 4 cents a share for the three months to Feb. 1. Analysts surveyed by Thomson Reuters had expected net income of 15 cents a share. Revenue of $610.2 million was 6.4% lower than a year earlier and missed expectations by $45.4 million. Comparable sales decreased 3.4% over the fourth quarter.

Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA

Shares of Ariad Pharmaceuticals closed up about 5% on Thursday with a little over 23 million shares traded. The stock was one of the biggest movers on the NASDAQ. Earlier in the week the company reported fourth quarter 2013 loss of 40 cents per share, wider than the year-ago loss of 36 cents per share but narrower than the Zacks Consensus Estimate of a loss of 46 cents per share. Fourth quarter revenues were $8.4 million, compared to $0.07 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $6 million. For 2013, ARIAD reported a loss of $1.49 per share, wider than the year-ago loss of $1.34 per share but narrower than the Zacks Consensus Estimate of a loss of $1.56 per share. Revenues were $45.6 million in 2013 as against $0.6 million in the previous year. Revenues surpassed the Zacks Consensus Estimate of $43 million.

Turbine Truck Engines Inc. (OTCBB: TTEG) – For an in-depth report on Turbine Truck Engines Inc. follow: www.BullTrends.com/stockquote/TTEG

Turbine Truck Engines closed up 54.89% on Thursday with about 4.1 million shares traded. The stock was one of the biggest gainers in the OTCBB market. The company announced that it has recently retired all convertible promissory notes originally issued to JMJ Financial in April 2012. Combined with TTE's announcement In September 2013 of having retired all convertible notes issued to Asher Enterprises, TTE has now removed all derivative liability debt from its balance sheet.

Workday, Inc. (NYSE: WDAY) - For an in-depth report on Workday, Inc. follow: www.BullTrends.com/stockquote/WDAY

Shares of WDAY closed up 15.15% on Thursday with nearly 6.5 million shares traded. The stock was one of the biggest gainers on the NYSE and hit a new 52-week high of $116.47 during intra-day trading. The stock was upgraded to “outperform" from "market perform" by FBR Capital. The analyst firm raised its price target for the software company to $150 from $84. Analyst Samad Samana said the upgrade is due to seeing higher sales demand across the board. Earlier in the week the company reported solid F4Q14 (January) results that beat consensus revenue and EPS estimates.”

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today